Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InDDEx: Exelon for Delaying Alzheimer's Diagnosis in MCI
NCT00000174Phase 3Completed
- Sponsor
- Novartis
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing Exelon with Placebo (2 arms). Primary endpoint: Time to clinical diagnosis of Alzheimer's disease at 48 months. Status: completed.
02
Drugs
rivastigmine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00000174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000174.